

Technology Advisory Interests Register

Topic: Obinutuzumab for treating lupus nephritis [ID6420]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	TAC Committee Member	Financial	Astellas Pharma - ongoing work with Astellas UK regarding gilteritinib for newly diagnosed acute myeloid leukemia Novartis - ongoing work with Novartis US regarding asciminib for newly diagnosed chronic myelogenous leukemia	18/11/2025	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal
Catherine Thompson	TAC Committee Member	Financial	I have received honoraria and payment for strategic advice from Roche (manufacturer), for other disease areas not related to this drug.	18/11/2025	It was agreed that Catherine's declaration would not prevent them from participating in discussions on this appraisal
Simon McNamara	TAC Committee Member	Financial	A GSK therapy is a comparator for ID6420. Given this, I am conflicted and so do not intend to attend.	13/11/2025	It was agreed that Simon's declaration would prevent them from participating in discussions on this appraisal
Professor Alan Salama	Expert	Direct - Financial	Honoraria from Roche – over 5 years ago (pre 2020)	10/12/2025	It was agreed that Alan's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					providing expert advice to the committee

DRAFT